臨床泌尿器科65巻2号

2011年02月発行

セミナー 泌尿器科医に必要なPET検査の知識―有用性と問題点・5

前立腺癌診療におけるPET（PET/CT）の役割

著者： 北島一宏¹² 千田道雄³ 杉村和朗²

所属機関： ¹先端医療センターPET診療部 ²神戸大学大学院医学系研究科生体情報医学講座放射線医学分野 ³先端医療センター分子イメージング研究グループ

ページ範囲：P.139 - P.148

要約　現在広く癌診断に使われている18F-FDGは前立腺癌に対して集積が低く，保険適応されていないが，海外では11Cコリン，11C酢酸，18Fコリンなどの核種を使用したPET検査の有用性が報告されている。治療前の前立腺癌の存在診断や病期診断などの評価は空間分解能の高いMRIが優れるが，治療後の再発・遠隔転移診断，治療前の予後予測，治療効果判定などでは有用性が期待される。

参考文献

1）Shreve PD, Grossman HB, Gross MD, et al：Metastatic prostate cancer：initial findings of PET with 2-Deoxy-2-［F-18］fluoro-D-glucose. Radiology 199：751-756, 1996

2）Liu IJ, Zafar MB, Lai YH, et al：Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Adult Urol 57：108-111, 2001

3）Oyama N, Akino H, Kanamaru H, et al：11C-acetate PET imaging of prostate cancer. J Nucl Med 43：181-186, 2002

4）Agus DB, Golde DW, Sgouros G, et al：Positron emission tomography of a human prostate cancer xenograft：association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58：3009-3014, 1998

5）Seltzer MA, Arbaric Z, Belldegrun A, et al：Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162：1322-1328, 1999

6）Morris MJ, Akhurst T, Osman I, et al：Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Adult Urol 59：913-918, 2002

7）Oyama N, Miller TR, Dehdashti F, et al：11C-acetate PET imaging of prostate cancer：detection of recurrent disease at PSA relapse. J Nucl Med 44：549-555, 2003

8）Fricke E, Machtens S, Hofmann M, et al：Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30：607-611, 2003

9）Schoder H, Herrmann K, Gonen M, et al：2-［18F］fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 11：4761-4769, 2005

10）Richter JA, Rodriguez M, Rioja J, et al：Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Bio（in press）

11）Salmine E, Hogg A, Binns D, et al：Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncologica 41：425-442 2002

12）Hara T, Kosaka N and Kishi H：PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39：990-995, 1998

uptake of（11C）choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 32：668-673, 2005

14）Kotzerke J, Prang J, Neumaicer B, et al：Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27：1415-1419, 2000

15）de Jong IJ, Pruim J, Elsinga PH, et al：11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44：32-38, 2003

16）Farsad M, Schiavina R, Castelluci P, et al：Detection and localization of prostate cancer：correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46：1642-1649, 2005

17）Martorana G, Schiavina R, Corti B, et al：11C-choline positron emission tomography-computed tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176：954-960, 2006

18）Reske SN, Blumstein NM, Neumaier B, et al：Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47：1249-1254, 2006

19）Scher B, Seitz M, Albinger W, et al：Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34：45-53, 2007

20）Rinnab L, Blumstein NM, Mottaghy FH, et al：11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 99：1421-1426, 2007

21）Testa C, Schiavina R, Lodi R, et al：Prostate cancer：sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 244：797-806, 2007

22）Schiavina R, Scattoni V, Castellucci P, et al：11C-choline positron emission tomography/computed tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer：comparison with clinical staging nomograms. Eur Urol 54：392-401, 2008

23）Giovacchini G, Picchio M, Coradeschi E, et al：［11C］Choline uptake with PET/CT for the initial diagnosis of prostate cancer：relation to PSA levels, tumor stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35：1065-1073, 2008

24）de Jong IJ, Pruim J, Elsinga PH, et al：Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-Choline PET. J Nucl Med 44：331-335, 2003

25）Harisinghani MG, Barentsz J, Hahn PF, et al：Noinvasive detection of clinically occult lymph node metastases in prostate cancer. N Eng J Med 348：2491-2499, 2003

26）Picchio M, Messa C, Landoni C, et al：Value of［11C］choline-positron emission tomography for re-staging prostate cancer：a comparison with［18F］fluorodeoxyglucose-positron emission tomography. Urology 169：1337-1340, 2003

27）Rinnab L, Mottaghy FM, Blumstein NM, et al：Evaluation of［11C］-choline positron-emisssion/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100：786-793, 2007

28）Krause BJ, Souvatzoglou M, Tuncel M, et al：The detection rate of［11C］choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35：18-23, 2008

29）Reske SN, Blumstein NM and Glatting G：［11C］choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35：9-17, 2008

30）Rinnab L, Simon J, Hautmann RE, et al：［11C］choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging 27：619-625, 2009

31）Kato T, Tsukamoto E, Kuge Y, et al：Accumulation of［11C］acetate in normal prostate and benign prostatic hyperplasia：comparison with prostate cancer. Eur J Nucl Med Mol Imaging 29：1492-1495, 2002

32）Kotzerke J, Volmer BG, Neumaier B, et al：Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med 29：1380-1384, 2002

33）Wachter S, Tomek S, Kurtaran A, et al：11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging with recurrent prostate cancer. J Clin Oncol 24：2513-2519, 2006

34）Sandblom G, Sorensen J, Lundin N, et al：Positron emission tomography with C11-acetate for tumor detection and localization with prostate-specific antigen relapse after radical prostatectomy. Urology 67：996-1000, 2006

35）Albrecht S, Buchegger F, Soloviev D, et al：11-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34：185-196, 2007

）after radical prostatectomy. BJU Int 99：1415-1420, 2007

37）Kotserke J, Volkmer BG, Glatting G, et al：Intraindividual comparison of［11C］acetate and［11C］choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42：25-30, 2003

38）Price DT, Colman RE, Liao RP, et al：Comparson of［18F］fluorocholine and［18F］fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168：273-280, 2002

39）Kwee SA, Coel MN, Lim J, et al：Prostate cancer localization with 18fluorocholine positron emission tomography. J Urol 173：252-255, 2005

40）Kwee SA, Wei H, Sesterhenn I, et al：Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl med 47：262-269, 2006

41）Hacker A, Jeschke S, Leeb K, et al：Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer：comparison of［18F］fluorocholine positron emission tomography, computed tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176：2014-2018, 2006

42）Igere I, Kohlfurst S, Gallowitsch HJ, et al：The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localization of prostate cancer. Eur J Nucl Med Mol Imaging 35：976-983, 2008

43）Husarik DB, Miralbell R, Dubs M, et al：Evaluation of［18F］-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35：253-263, 2008

44）Schmid DT, John H, Zweifel R, et al：Fluorocholine PET/CT in patients with prostate cancer：initial experience. Radiology 235：623-628, 2005

45）Cimitan M, Bortolus R, Morassut S, et al：［（18）F］flurocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse：experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33：1387-1398, 2006

? Mol Imaging Biol 8：43-48, 2006

47）Beheshti M, Vali R, Waldenberger P, et al：Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT：a comparative study. Eur J Nucl Med Mol Imaging 35：1766-1774, 2008

48）Beheshti M, Vali R, Waldenberger P, et al：The use of F-18 choline PET in the assessment of bone metastases in prostate cancer：correlation with morphological changes on CT. Mol Imaging Biol 11：446-454, 2009

49）Kwee SA, Coel MN, Ly BH, et al：18F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Ann Nucl Med 23：541-548, 2009

Tc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47：287-297, 2006